Top Page
Diaceutics
(OTC:DXRX)
Diaceutics (DXRX) vs. iShares MSCI United Kingdom ETF (EWC)
Diaceutics Business Overview & Revenue Model
Diaceutics Earnings Call Summary
Diaceutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.40M | 32.16M | 23.70M | 19.50M | 13.94M | 12.70M |
| Gross Profit | 29.63M | 28.27M | 19.71M | 14.04M | 10.57M | 9.33M |
| EBITDA | 2.69M | 2.77M | 2.36M | 3.61M | 2.35M | 178.00K |
| Net Income | -1.52M | -1.70M | -1.75M | 724.00K | 561.00K | 263.00K |
Balance Sheet | ||||||
| Total Assets | 44.42M | 48.62M | 46.34M | 48.26M | 45.01M | 43.52M |
| Cash, Cash Equivalents and Short-Term Investments | 10.38M | 12.74M | 16.67M | 19.84M | 19.68M | 25.25M |
| Total Debt | 1.13M | 1.06M | 1.21M | 1.33M | 1.56M | 118.00K |
| Total Liabilities | 7.18M | 8.76M | 5.56M | 5.74M | 4.36M | 3.28M |
| Stockholders Equity | 37.24M | 39.86M | 40.79M | 42.51M | 40.65M | 40.24M |
Cash Flow | ||||||
| Free Cash Flow | 10.00K | -3.98M | -3.54M | 278.00K | -5.03M | -6.04M |
| Operating Cash Flow | 104.00K | 651.00K | 1.31M | 5.15M | 570.00K | 253.00K |
| Investing Cash Flow | -5.76M | -4.03M | -4.21M | -4.87M | -5.60M | -6.29M |
| Financing Cash Flow | -242.00K | -64.00K | -239.00K | -132.00K | -270.00K | 19.61M |
Diaceutics Technical Analysis
Diaceutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | £110.44M | 19.26 | 8.71% | ― | -1.43% | 28.57% | |
64 Neutral | £138.74M | -91.11 | -3.95% | ― | 31.83% | 46.59% | |
53 Neutral | £311.64M | ― | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £9.46M | -0.26 | -122.54% | ― | -57.03% | -15.71% | |
46 Neutral | £102.22M | -7.46 | ― | ― | ― | -94.12% | |
40 Underperform | ― | ― | -87.18% | ― | 29.64% | 28.51% |
Diaceutics Corporate Events
Diaceutics PLC has announced the purchase of ordinary shares by trustees of the Global Diaceutics plc 2020 Employee Benefit Trust on behalf of certain PDMRs under the company’s UK and Global Share Incentive Plan. The company has matched these purchases with a share award, and issued 5,176 shares to the UK Trust to facilitate trading. This move is part of their ongoing commitment to incentivize employees and aligns with their strategy to enhance stakeholder value.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £2.25 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics Plc is a leading technology and solutions provider in the pharma and biotech industry, specializing in the commercialization of precision medicines through data analytics and advisory services. The company operates primarily through its DXRX platform, which facilitates the integration of diagnostics and therapeutics.
Diaceutics PLC reported strong financial results for the first half of 2025, with a 22% revenue growth on a constant currency basis, reaching £14.6 million. The company is on track to achieve full-year profitability, supported by a solid order book and increased annual recurring revenue. Diaceutics has expanded its customer base and therapeutic brands, reinforcing its position as a primary commercialization partner for pharma and biotech companies. The company has made significant investments in AI and platform upgrades, which are expected to drive future growth and operational leverage. Despite global economic uncertainties, Diaceutics remains confident in meeting its profitability targets for 2025, highlighting its strategic focus on precision medicine and sustainable profitability.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £147.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics PLC announced it will release its unaudited half-year results for the period ending 30 June 2025 on 23 September 2025. The company will also hold a webinar presentation for analysts and investors on the same day, indicating a proactive approach to engaging stakeholders and maintaining transparency in its operations.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £147.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics PLC has announced that Global Shares Trustees (UK) Limited and Zedra Trust Company (Guernsey) Limited have purchased ordinary shares on behalf of key personnel under the company’s Share Incentive Plan (SIP). The company has matched these purchases with a 1:1 share award, issuing 6,218 shares to the UK Trust. This move increases Diaceutics’ total shares in issue to 84,880,396, which may impact shareholder notifications under FCA rules.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £147.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics PLC announced its participation in the Canaccord Genuity 45th Annual Growth Conference, highlighting its role as a prominent player in the pharma and biotech sectors. This event presents an opportunity for Diaceutics to engage with global investors and showcase its innovative solutions, potentially enhancing its market positioning and stakeholder engagement.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics PLC has announced the purchase of ordinary shares by trustees on behalf of key personnel as part of its UK and Global Share Incentive Plan. The company has matched these purchases with a 1:1 share award, reflecting its commitment to employee incentives and aligning interests with stakeholders. This move is part of a broader strategy to facilitate share trading and enhance transparency in shareholding, with implications for shareholder notifications under regulatory guidelines.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics PLC has appointed Lauren DeWitt as Executive Vice President, Legal, General Counsel, and Group Company Secretary. With her extensive legal experience in the pharmaceutical sector, including roles at Sandoz and Novartis, DeWitt is expected to significantly contribute to Diaceutics’ strategic growth and legal functions. Her expertise in litigation, regulatory, and transactional legal functions aligns with the company’s growth ambitions, positioning Diaceutics to enhance its leadership team and support its mission in precision medicine.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics PLC has announced the issuance of 1,886,357 share options to its directors, senior management, and key staff as part of its Employee Share Option Plan. This move is aligned with the company’s long-term incentive plan, aiming to enhance performance through specific criteria such as Total Shareholder Return, revenue growth, and EBITDA margin. The share options, which represent approximately 7.32% of the company’s current issued share capital, are set to vest over a three-year period, reflecting Diaceutics’ commitment to aligning employee incentives with company performance and shareholder interests.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.